. 2022 Feb 1;40(12):1855–1863. doi: 10.1016/j.vaccine.2022.01.055

Table 3.

Convergent Validity.

Items	C1: Consequence				C2: Uncertainty				C3: Action
Items	α	CR	AVE	L	Α	CR	AVE	L	α	CR	AVE	L
MA1	0.80	0.883	0.69	0.828	0.78	0.870	0.69	0.810	0.81	0.887	0.72	0.813
MA2				0.879				0.823				0.873
MA3				0.832				0.859				0.864
BP1	0.78	0.868	0.72	0.821	0.80	0.880	0.71	0.832	0.77	0.869	0.68	0.857
BP2				0.795				0.832				0.806
BP3				0.869				0.865				0.811
RP 1	0.71	0.837	0.63	0.827	0.73	0.841	0.64	0.821	0.74	0.803	0.58	0.803
RP 2				0.785				0.826				0.745
RP 3				0.773				0.746				0.728
PAV1	0.84	0.902	0.75	0.886	0.82	0.891	0.73	0.891	0.85	0.912	0.77	0.888
PAV2				0.896				0.871				0.911
PAV3				0.822				0.802				0.842

Items	C4: Reassurance				C5: Conflict				C6: New Evidence
Items	α	CR	AVE	L	Α	CR	AVE	L	α	CR	AVE	L
MA1	0.82	0.893	0.77	0.856	0.81	0.886	0.72	0.855	0.78	0.874	0.70	0.844
MA2				0.904				0.889				0.852
MA3				0.812				0.802				0.810
BP1	0.76	0.856	0.65	0.766	0.79	0.889	0.69	0.815	0.76	0.855	0.66	0.757
BP2				0.778				0.793				0.787
BP3				0.897				0.881				0.896
RP 1	0.72	0.840	0.67	0.798	0.76	0.859	0.671	0.862	0.72	0.829	0.619	0.806
RP 2				0.802				0.765				0.809
RP 3				0.793				0.827				0.743
PAV1	0.81	0.885	0.72	0.899	0.85	0.913	0.78	0.875	0.79	0.880	0.71	0.859
PAV2				0.899				0.901				0.895
PAV3				0.737				0.867				0.769

RP = Risk Perception, BP = Benefit Perception, MA = Media Attention, and PAV = Public acceptance of COVID-19 Vaccine, L = item loading, CR = Composite Reliability, and AVE = Average Variance Extracted.